Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 3:2018:2146080.
doi: 10.1155/2018/2146080. eCollection 2018.

A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer

Zeyad R Schwen  1 , Mohit Gupta  1 , Phillip M Pierorazio  1
Affiliations
Review

A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer

Zeyad R Schwen et al. Adv Urol. .

Abstract

Objectives: The robotic-assisted laparoscopic retroperitoneal lymph node dissection (R-RPLND) represents a new frontier in the surgical management of testicular cancer in the realm of minimally invasive urologic oncology. We aimed to review the early outcomes as compared to the laparoscopic and open approaches as well as describe the operative technique for the R-RPLND.

Materials and methods: We reviewed all the literature related to the R-RPLND based on an electronic PubMed search up until July 2017.

Results and discussion: Encouraged by favorable early oncologic and safety outcomes for treatment of clinical stage (CS) I nonseminomatous germ cell tumor (NSGCT), the R-RPLND affords the same recovery advantages as the laparoscopic retroperitoneal lymph node dissection (L-RPLND) while offering greater dexterity, superior visualization, and a theoretically shorter learning curve for the surgeon. While R-RPLND has a promising future in the management of patients with primary and postchemotherapy NSGCT, larger and more vigorous prospective studies are needed before supplanting the open RPLND as the gold standard approach for primary low-stage NSGCT or becoming an equivalent surgical modality in the postchemotherapy setting.

PubMed Disclaimer

References

    1. Motzer R. J., Jonasch E., Agarwal N., et al. Testicular cancer, version 2.2015. 2015;13(6):772–799. - PubMed
    1. Cary C., Masterson T. A., Bihrle R., Foster R. S. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: additional procedures and perioperative complications. 2015;33(9):389 e15–389 e21. doi: 10.1016/j.urolonc.2014.07.013. - DOI - PubMed
    1. Macleod L. C., Rajanahally S., Nayak J. G., et al. Characterizing the morbidity of postchemotherapy retroperitoneal lymph node dissection for testis cancer in a national cohort of privately insured patients. 2016;91:70–76. doi: 10.1016/j.urology.2016.01.010. - DOI - PMC - PubMed
    1. Subramanian V. S., Nguyen C. T., Stephenson A. J., Klein E. A. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. 2010;28(5):504–509. doi: 10.1016/j.urolonc.2008.10.026. - DOI - PubMed
    1. Bhayani S. B., Ong A., Oh W. K., Kantoff P. W., Kavoussi L. R. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. 2003;62(2):324–327. doi: 10.1016/s0090-4295(03)00324-8. - DOI - PubMed

LinkOut - more resources